Democratic lawmakers ask Musk for info on possible Chinese manipulation of Twitter
Three Democratic House members are calling on Elon Musk to provide information about a possible Twitter manipulation campaign by the Chinese government.
A rare fund in the green this year succeeds by betting on stocks that work even in a recession
The Invesco Comstock Select fund outperformed this year because of a patient, contrarian approach to stock picking.
Congress expected to repeal Pentagon’s Covid vaccine mandate for U.S. troops
The overwhelming majority of Marines, soldiers and sailors have been vaccinated against Covid, but several thousand have been kicked out for refusing the shots.
Here’s how to use Lensa, the chart-topping app that uses AI to transform your selfies into digital avatars
Lensa is the top free app on Apple’s App Store. For a small fee, it turns your selfies into AI-generated digital art. Here’s how it works.
Markets are bracing for a ‘Powell recession’ that could be coming soon
The bond market is now pricing in the near certainty of a recession, induced by the Fed, that already is here or on the way shortly.
Biden to require new federal buildings to slash greenhouse gas emissions
The decision comes as a growing number of cities have voted to curb gas consumption in buildings.
This little-known lithium stock is set to surge more than 60% next year, Cowen predicts
The investment bank said investors are underappreciating likely catalysts that can push the stock higher.
Tax-trimming strategies tailored for the ETF investor
For ETF investors bearing the brunt of a down market in 2022, tax-loss harvesting might offer an opportunity to redeem some of this year’s setbacks.
‘Risky behaviors’ are causing credit scores to level off — here’s how that can hurt you
Your three-digit credit score can determine the interest rate you’ll pay for credit cards, car loans and mortgages. The higher your score, the lower the rate.
FDA expected to decide on Pfizer RSV vaccine for older adults by May 2023
Pfizer said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.
